ReviewAnnals of gastroenterology
New insights into irritable bowel syndrome: from pathophysiology to treatment.
Review in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Acupuncture for Adults with Diarrhea-Predominant Irritable Bowel Syndrome or Functional Diarrhea: A Systematic Review and Meta-Analysis.Neural plasticity · 2020Pooled it
- Trial
- Occult constipation masking as irritable bowel syndrome with predominant diarrhea in Bangladeshi children.World journal of gastrointestinal pathophysiology · 2026Article
- Deciphering the mitochondria-gut microbiota axis in irritable bowel syndrome: pathogenic insights and therapeutic frontiers.Journal of translational medicine · 2026Review
- Gastrointestinal microbiota and inflammasomes interplay in health and disease: a gut feeling.Gut · 2025Review
- Melatonin alleviates diarrhea and visceral hypersensitivity in rats with diarrhea-predominant irritable bowel syndrome by modulating of the TLR4/MyD88/NF-κB pathway.BMC gastroenterology · 2025Article
- Aberrant functional connectivity patterns in the pregenual anterior cingulate cortex and anterior midcingulate cortex of patients with irritable bowel syndrome accompanied by depressive symptoms.Brain imaging and behavior · 2025Article
- Tea-derived exosome-like nanoparticles prevent irritable bowel syndrome induced by water avoidance stress in rat model.Journal of gastroenterology and hepatology · 2024Article
- Article
- Functional Abdominal Bloating and Gut Microbiota: An Update.Microorganisms · 2024Review
- Rapid biotransformation of STW 5 constituents by human gut microbiome from IBS- and non-IBS donors.Microbiology spectrum · 2024Article
- Article
- Development and Validation of a High-Performance Liquid Chromatography Method to Quantify Marker Compounds inMolecules (Basel, Switzerland) · 2024Article
- Risk Factors of Developing Postinfectious Irritable Bowel Syndrome in Shigellosis Patients, 5 Years After Hospitalization During the Outbreak.Open forum infectious diseases · 2024Article
- The critical role of gut-brain axis microbiome in mental disorders.Metabolic brain disease · 2023Review
- Therapeutic effects of curcumin on constipation-predominant irritable bowel syndrome is associated with modulating gut microbiota and neurotransmitters.Frontiers in microbiology · 2023Article
- Functional Implications and Clinical Potential of MicroRNAs in Irritable Bowel Syndrome: A Concise Review.Digestive diseases and sciences · 2023Review
- How Tongxie-Yaofang Regulates Intestinal Synaptic Plasticity by Activating Enteric Glial Cells and NGF/TrkA Pathway in Diarrhea-Predominant Irritable Bowel Syndrome Rats.Drug design, development and therapy · 2023Article
- Bifidobacterium bifidum and Bacteroides fragilis Induced Differential Immune Regulation of Enteric Glial Cells Subjected to Exogenous Inflammatory Stimulation.Inflammation · 2022Article
- Modulation of Intestinal Corticotropin-Releasing Hormone Signaling by the Herbal Preparation STW 5-II: Possible Mechanisms for Irritable Bowel Syndrome Management.Pharmaceuticals (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irritable bowel syndrome (IBS) is the most common reason to visit a gastroenterologist. IBS was believed to be a functional disease, but many possible pathophysiologic mechanisms can now explain the symptoms. IBS patients are classified into subtypes according to their predominant bowel habit, based on the Rome IV criteria. These include diarrhea-predominant and constipation-predominant IBS, as well as the mixed type, a combination of the two. Usually, IBS treatment is based on the predominant symptoms, with many options for each subtype. A new promising treatment option, fecal microbiota transplantation, seems to have beneficial effects on IBS. However, treating the pathophysiological causative agent responsible for the symptoms is an emerging approach. Therefore, before the appropriate therapeutic option is chosen for treating IBS, a clinical evaluation of its pathophysiology should be performed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.